

**Claim Amendments:**

Claim 1. (Previously presented): A solid pharmaceutical composition in tablet form for oral administration comprising a benzofuran derivative with antiarrhythmic activity selected from the group consisting of dronedarone and amiodarone, or a pharmaceutically acceptable salt thereof, as an active principle, and a pharmaceutically acceptable nonionic hydrophilic surfactant selected from poloxamers, optionally in combination with one or more pharmaceutical excipients, said nonionic hydrophilic surfactant being present in a proportion of from 5% to 15% by weight of the active principle in base form, provided that the pharmaceutical composition does not contain a polysorbate surfactant.

Claim 2. (Currently amended): A pharmaceutical composition according to Claim 1~~Claim 4~~, wherein the benzofuran derivative is dronedarone hydrochloride.

Claim 3. (Currently amended): A pharmaceutical composition according to Claim 1~~Claim 4~~, wherein the benzofuran derivative is amiodarone hydrochloride.

Claim 4. (Previously presented): A pharmaceutical composition according to claim 1 wherein the pharmaceutically acceptable salt is the hydrochloride.

Claim 5. (Cancelled)

Claim 6. (Previously presented): A pharmaceutical composition according to Claim 1 wherein the nonionic hydrophilic surfactant is selected from the group consisting of poloxamer 124, poloxamer 188, poloxamer 237, poloxamer 338, and poloxamer 407.

Claim 7. (Previously presented): A pharmaceutical composition according to claim 6 wherein the nonionic hydrophilic surfactant is poloxamer 407.

Claims 8-10. (Cancelled)

Claim 11. (Previously presented): A pharmaceutical composition according to Claim 6 containing from 50 to 500 mg of active principle.

Claim 12. (Previously presented): A pharmaceutical composition according to Claim 11, containing from 200 to 400 mg of active principle.

Claim 13. (Previously presented): A pharmaceutical composition according to Claim 12, containing from 200 to 400 mg of active principle, calculated in base form, and 10% by weight of nonionic hydrophilic surfactant relative to the active principle in base form.

Claims 14-15. (Cancelled)

Claim 16. (Previously presented): A pharmaceutical composition according to Claim 7 wherein the benzofuran derivative is dronedarone hydrochloride.

Claims 17-18. (Cancelled)

Claim 19. (Previously presented): A pharmaceutical composition according to Claim 7 wherein the benzofuran derivative is amiodarone hydrochloride.

Claim 20. (Currently amended): A pharmaceutical composition according to Claim 13 wherein the active principle is selected from the group consisting of amiodarone hydrochloride and dronedarone hydrochloride ~~or a pharmaceutically acceptable salt thereof.~~

Claim 21. (Previously presented): A pharmaceutical composition according to claim 20 wherein the nonionic hydrophilic surfactant is poloxamer 407.

Claim 22. (Previously presented): A pharmaceutical composition according to claim 21 wherein the active principle is dronedarone hydrochloride.